LIVE WEBINAR: Thursday, June 24, 2021, 5:00 PM – 6:00 PM Eastern Time

Summer Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma

Register Now

Register for this complimentary event with the “Register Now ” button above,
which will take you to our Zoom registration page.

Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, June 24, 2021, 5:00 PM – 6:00 PM ET

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alli McClanahan, MSN, APRN, ANP-BC
Nurse Practitioner
Division of Hematology
Mayo Clinic
Rochester, Minnesota


This activity is supported by an educational grant from Bristol-Myers Squibb Company.

Topics to Be Discussed

  • Overview, biologic rationale and mechanisms of action of chimeric antigen receptor (CAR) T-cell therapy
  • Process of producing and administering CAR T-cell therapies
  • Similarities and differences among approved and investigational CAR T-cell platforms
  • Spectrum, frequency, timing and severity of adverse events associated with CAR T-cell therapies, including cytokine release syndrome and neurologic toxicities; counseling patients and families about potential side effects; effective management strategies
  • Published efficacy and safety outcomes with and ongoing investigation of B-cell maturation antigen-targeted CAR T-cell therapies for multiple myeloma (MM); emerging results from the pivotal Phase II KarMMa study of idecabtagene vicleucel for relapsed/refractory MM
  • Idecabtagene vicleucel: Recent FDA approval, indication for use, practical incorporation into the treatment algorithm and future investigational strategies

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational CAR T-cell products.
  • Appraise available data supporting the recent FDA approval of idecabtagene vicleucel for the treatment of relapsed or refractory MM, and determine how this therapy can be appropriately integrated into treatment decision-making.
  • Recognize common adverse events associated with CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall ongoing research evaluating CAR T-cell-based approaches for patients with MM, and counsel appropriate patients regarding the potential benefits of trial participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs McClanahan has no relevant conflicts of interest to disclose. The following faculty (and their spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr RajeConsulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Bristol-Myers Squibb Company.